MedTrace Logo

Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

NCT06227221 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-02-12

No results posted yet for this study

Summary

The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.

Conditions

Interventions

DRUG

Sorafenib

Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.

DRUG

Placebo

Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2028-10-31
Completion
2029-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06227221 on ClinicalTrials.gov